HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages MultiPlan (MPLN) and ZoomInfo (ZI) Investors with Losses to Contact Its Attorneys, Firm Investigating Possible Securities Fraud

SAN FRANCISCO, Nov. 23, 2020 (GLOBE NEWSWIRE) — Hagens Berman updates investors in the following publicly-traded companies and urges investors who have suffered significant losses to contact the firm. Further details about the investigations can be found at the links provided.

MLPN Investors Click Here.
ZI Investors Click Here.


MultiPlan Corporation (MPLN) Investigation

:

Relevant Holding
Period: Before Nov. 11, 2020
Visit:www.hbsslaw.com/investor-fraud/MPLN
Contact An Attorney Now:MPLN@hbsslaw.com
                                             844-9160895

The investigation centers on MultiPlan’s financial disclosures leading up to- and through- its merger and going public transaction with special purpose acquisition (“SPAC”) company Churchill Capital Corp. III.

More specifically, Hagens Berman is investigating the company’s and its sponsor’s statements about MultiPlan’s client base and revenues.

On Nov. 11, 2020, Muddy Waters Capital published a scathing report, “MultiPlan: Private Equity Necrophilia Meets The Great 2020 Money Grab,” based in part on its interviews of former MultiPlan executives.

Among other things, Muddy Waters observes: (1) the company and its sponsors concealed the impending loss of MultiPlan’s largest client (“UnitedHealthcare”, or “UHC”) due to UHC’s formation of a competitor (“Naviguard”) that offers significantly lower prices and fewer conflicts of interest; (2) MultiPlan’s financials “have been financially engineered to obscure the decay in its business;” and, (3) “[w]e understand that in 2018, MPLN released revenue reserves, dropping them from approximately 30% to 10% of revenue, which we believe enabled MPLN to show 2018 EBITDA growth amid shrinking sales.”

Concluding, Muddy Waters states “MPLN paints a rosy picture of its prospects, but these are inconsistent with the facts: its revenue peaked in 2017, and Naviguard is never once mentioned by management as a threat” and “we are concerned that management’s strategy carries the potential to bankrupt MPLN.”

“We’re focused on investors’ losses and whether MultiPlan misrepresented its client base and revenues,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you are a MultiPlan investor and have significant losses, or have knowledge that may assist the firm’s investigation, click here to discuss your legal rights with Hagens Berman.


ZoomInfo Technologies (ZI) Investigation

:

Relevant Holding
Period: Before Nov. 10, 2020
Visit:www.hbsslaw.com/investor-fraud/ZI
Contact An Attorney Now:ZI@hbsslaw.com
                                             844-9160895

Hagens Berman is investigating ZoomInfo’s compliance with accounting rules (“GAAP”) governing the reporting of certain tax benefits.

More specifically, on Nov. 9, 2020, ZoomInfo announced that on Nov. 5, 2020 its audit committee of the board of directors concluded the company’s Q2 2020 financial statements filed with the SEC should not be relied on.

ZoomInfo further revealed it would restate those results because it improperly recorded a $21.6 million tax benefit related to the GAAP basis and tax basis of partnerships owned by corporations within ZoomInfo’s corporate structure. As a result of this improper accounting, ZoomInfo understated its Q2 2020 net loss by over 38%.

“We’re focused on investors’ losses and whether ZoomInfo intentionally manipulated the GAAP/tax basis differential of certain assets to present a misleading picture of the company’s true financial results,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

If you are a ZoomInfo investor and have significant losses, or have knowledge that may assist the firm’s investigation, click here to discuss your legal rights with Hagens Berman.

Whistleblowers: Persons with non-public information regarding MultiPlan and/or ZoomInfo should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 8449160895 or email MPLN@hbsslaw.com and/or ZI@hbsslaw.com.


About Hagens Berman


Hagens Berman is a national law firm with nine offices in eight cities around the country and eighty attorneys. The firm represents investors, whistleblowers, workers and consumers in complex litigation.   More about the firm and its successes is located at hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

Contact
:

Reed Kathrein, 844-916-0895 



ACWA Virtual Fall Conference Features California Water Leaders and Experts

SACRAMENTO, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) — The Association of California Water Agencies (ACWA) will host its 2020 Fall Virtual Conference & Exhibition on Dec. 2-3 and include a post-election analysis among numerous forums and programs featuring the latest developments within California water.

The event temporarily replaces one of ACWA’s semi-annual in-person conferences and is the second virtual conference this year. As with all ACWA conferences, a line-up of keynote speakers will address attendees on a variety of top issues within the water industry.

Fall conference keynote speakers will include Daniel Swain, who will discuss climate change and a recent analysis released by the Union of Concerned Scientists. Also, California Environmental Protection Agency Secretary Jared Blumenfeld will join California Natural Resources Agency Secretary Wade Crowfoot and California Department of Food and Agriculture Secretary Karen Ross for a discussion on implementing Gov. Gavin Newsom’s Water Resilience Portfolio.

The conference opens Dec. 2 with a keynote address by Lucas Public Affairs Executive Vice President and Chief Strategy Officer Cassandra Pye, who will discuss leadership and the importance of racial and gender diversity in the workplace. Also, former ACWA Executive Director Timothy Quinn will speak as a Stanford University Fellow and deliver a keynote address on the evolution of effective water management in California.

Additionally, the virtual event will include forums and programs focused on top issues affecting California water agencies, including an expert panel on expected impacts stemming from the 2020 election from a state and national perspective. Forums and panels will also focus on wildfires, state funding for safe drinking water, COVID-19 financial consequences and U.S. Supreme Court rulings on water rights, among other topics.

The full conference program with event dates, specific times and a full list of keynote speakers is available online. News media interested in covering parts of the virtual conference can make arrangements for accessing it by contacting ACWA Communications Director Heather Engel at heathere@acwa.com or by calling (760) 217-0627.

WHAT: ACWA’s 2020 Fall Virtual Conference & Exhibition
WHEN: Wednesday, Dec. 2, 8 a.m. – 5:15 p.m.
  Thursday, Dec. 3, 8 a.m. – noon

ACWA is a statewide association of public agencies whose more than 450 members are responsible for about 90% of the water delivered in California. For more information, visit www.acwa.com

Contact: Heather Engel, Director of Communications |C (760) 217-0627



OnCourse Learning and Timea’s Cause Launch Educational Portal Aimed at Fighting Pandemic-Driven Growth in Modern Slavery and Human Trafficking

OnCourse Learning and Timea’s Cause Launch Educational Portal Aimed at Fighting Pandemic-Driven Growth in Modern Slavery and Human Trafficking

BROOKFIELD, Wis.–(BUSINESS WIRE)–
OnCourse Learning, a leading provider of regulatory and compliance education solutions for the mortgage and financial sectors, and Timea’s Cause, a Toronto-based advocacy organization focused on the fight against human trafficking, are today announcing the launch of an innovative online education platform dedicated to fighting modern slavery and human trafficking in all its form. The TC Online initiative, powered by OnCourse Learning technology, targets human trafficking, a transnational crime that has worsened during the COVID-19 pandemic, according to the UN Office of Drugs and Crime (UNODC).

The TC Online Institute seeks to offer high-level, live and interactive training and educational services to career professionals in law enforcement, healthcare, hospitality, the financial sector and other industries impacted by forced labor, sex trafficking, domestic servitude, organ trafficking, forced marriages and other iterations of modern slavery. Law enforcement efforts to fight these crimes have been hindered by the coronavirus pandemic, while the global economic downturn has made children particularly vulnerable to traffickers, the UNODC said in May.

The joint initiative builds upon the work of Timea Nagy, a Toronto-based sex-trafficking survivor who in 2009 founded “Walk With Me,” a nonprofit organization that provides shelter and services for the survivors of human trafficking. Since launching Timea’s Cause in 2014, Nagy has shared her story at the United Nations and with news networks and public- and private-sector entities around the globe. In addition to providing educational resources on modern slavery and human trafficking, the organization also funds survivor support programs, prevention initiatives and advocacy work throughout North America.

As an extension of that effort, TC Online Institute will provide an array of educational materials, including webinars and virtual courses, aimed at helping more than 50,000 career professionals, parents, youths and other socially-conscious allies in their efforts to identify and prevent modern slavery and rehabilitate those who have survived it.

“We are extremely honored to be working with Timea’s Cause on this innovative initiative, particularly as the COVID-19 pandemic has exacerbated trafficking targeting children,” said OnCourse Learning President Josh Braunstein. “Modern slavery and human trafficking impact more than 40 million people worldwide every year, but most will never have the chance to attend a class or show up to a learning center in person. Our hope is that, by utilizing OnCourse Learning’s business model, the TC Online Institute will serve as an easily accessible Internet portal for those who are seeking help or to help others.”

“Although our work with OnCourse Learning began in 2017, it has grown this year in part because we needed a way to continue educating people without exposing them to the risks of the COVID-19 virus,” said Nagy. “That led to a collaboration that we hope will help thousands of victims of modern slavery and human trafficking over the next decade. I’m very proud to take the work of Timea’s Cause to the next level with the TC Online Institute.”

The two organizations most recently collaborated in 2019 with the launch of the Human Trafficking & Smuggling Course, a free 60-minute online experience for the compliance staff of financial institutions that includes video, interactive audio exercises and real-life examples of the crimes. Participants in the course, which was developed in conjunction with OnCourse Learning’s sister company ACAMS, also receive a post assessment and certificate of completion upon finishing the training.

About OnCourse Learning

OnCourse Learning is a member of Adtalem Global Education (NYSE: ATGE), a global education provider headquartered in the United States. It empowers financial institutions to prepare their frontlines, compliance teams, executive leadership and board of directors with comprehensive enterprise compliance, risk management and professional development education that is effective and engaging. Over 10,000 clients and partners have adopted OnCourse Learning solutions to efficiently manage complexity, change and growth. Plus, over the course of our 40+ year history we have trained over 200,000 individuals with our NMLS-approved licensure and continuing education courses.

About Adtalem Global Education

The purpose of Adtalem Global Education is to empower students to achieve their goals, find success, and make inspiring contributions to our global community. Adtalem Global Education Inc. (NYSE: ATGE; member S&P MidCap 400 Index) is a leading workforce solutions provider and the parent organization of American University of the Caribbean School of Medicine, Association of Certified Anti-Money Laundering Specialists, Becker Professional Education, Chamberlain University, EduPristine, OnCourse Learning, Ross University School of Medicine and Ross University School of Veterinary Medicine. For more information, please visit adtalem.com and follow us on Twitter (@adtalemglobal) and LinkedIn.

About TC Online Institute

TC Online Institute was conceived and developed by Timea’s Cause, an innovative social enterprise leading the fight against human trafficking through advocacy, rescue, rehabilitation efforts, awareness, and education. Timea’s Cause was created by global activist and human trafficking survivor Timea Nagy. From law enforcement, service providers, hospitality and financial sector leaders, to parents, youth, and other socially-conscious public allies, the team at Timea’s Cause has decades of experience teaching a diverse cross-section of public and private sector people about the complicated fabric of human trafficking.

Ann Reist

areist@oncourselearning.com

630-674-6927

KEYWORDS: Wisconsin United States North America

INDUSTRY KEYWORDS: Other Consumer Philanthropy Continuing Training University Consumer Other Philanthropy Foundation Education

MEDIA:

Genentech Announces FDA Approval of Xofluza for the Prevention of Influenza Following Contact With an Infected Person

Genentech Announces FDA Approval of Xofluza for the Prevention of Influenza Following Contact With an Infected Person

Xofluza is the first single-dose influenza medicine approved to prevent influenza for those who have had contact with an infected person (post-exposure prophylaxis) –

Genentech also provides an update on the sNDA filing for Xofluza in the pediatric setting

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza® (baloxavir marboxil) as a treatment to prevent influenza in people 12 years of age and older following contact with someone with influenza (known as post-exposure prophylaxis). Xofluza is the first single-dose influenza medicine approved for post-exposure prophylaxis.

“With today’s approval, Xofluza is now available as the first single-dose, post-exposure preventive treatment for influenza,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. “We’re hopeful that reducing the burden of influenza may help to mitigate the strain on our healthcare system amid the COVID-19 pandemic.”

Post-exposure prophylaxis with single-dose Xofluza was evaluated in the Phase III BLOCKSTONE study, which was recently published in The New England Journal of Medicine. BLOCKSTONE evaluated Xofluza compared with placebo as a preventive treatment for household members (adults and children) who were living with someone with influenza. Xofluza showed a statistically significant prophylactic effect on influenza after a single oral dose in people exposed to an infected household contact. The proportion of household members 12 years of age and older who developed influenza was 1% in participants treated with Xofluza and 13% in the placebo-treated group. Xofluza was well tolerated in this study and no new safety signals were identified.

“The flu is a serious illness that burdens households and sickens millions across the U.S. every year,” said Serese Marotta, Chief Operating Officer at Families Fighting Flu. “As we are about to enter a flu season within a global COVID-19 pandemic, we welcome Xofluza as a single-dose flu medicine to be used preventively after exposure to flu.”

The most frequently reported adverse events (occurring in at least 1% of adult and adolescent influenza patients treated with Xofluza) included diarrhea (3%), bronchitis (3%), nausea (2%), sinusitis (2%), and headache (1%).

Additionally, Genentech is determining a path forward with the FDA for a potential indication for Xofluza as a treatment for acute uncomplicated influenza in otherwise healthy children (one to 12 years of age) and for the prevention of influenza in the same age group who have been exposed to influenza. Xofluza is currently not approved for use in this population.

Xofluza is already FDA-approved to treat acute uncomplicated influenza in people 12 years of age and older who have had influenza symptoms for no more than 48 hours and who are otherwise healthy or at high risk of developing influenza-related complications. Although some of the symptoms of COVID-19 and influenza can look similar, the two illnesses are caused by completely different viruses. Xofluza is specifically designed to treat influenza viruses only and is not effective against SARS-CoV-2, the coronavirus causing COVID-19.

About BLOCKSTONE

BLOCKSTONE is a Phase III, double-blind, multicenter, randomized, placebo-controlled, post-exposure prophylaxis study that evaluated a single dose of Xofluza compared with placebo in household members (adults and children) who were living with someone with influenza confirmed by a rapid influenza diagnostic test (the ‘index patient’). The study was conducted by Shionogi & Co., Ltd. in Japan during the 2018-2019 influenza season.

Those diagnosed with influenza were required to have onset of symptoms for less than 48 hours and participants were required to have lived with those diagnosed for more than 48 hours. The participants were randomized to receive a single dose of Xofluza (dose according to body weight) or placebo as a preventive measure against developing influenza.

About Xofluza® (baloxavir marboxil)

Xofluza is a first-in-class, single-dose oral medicine with an innovative proposed mechanism of action that has demonstrated efficacy in a wide range of influenza viruses, including in vitro activity against oseltamivir-resistant strains and avian strains (H7N9, H5N1) in non-clinical studies. Xofluza is the first in a class of antivirals designed to inhibit the cap-dependent endonuclease protein, which is essential for viral replication.

Xofluza is available in the U.S. and in several other countries for the treatment of influenza types A and B. In the U.S., Xofluza is approved for the treatment of acute, uncomplicated influenza in people 12 years of age and older who are otherwise healthy or at high risk of developing serious complications from influenza, and who have been symptomatic for no more than 48 hours. Xofluza is also approved for post-exposure prophylaxis of influenza in people 12 years of age and older following contact with an individual who has influenza. Xofluza was the first new antiviral to be approved by the FDA in 20 years.

Robust clinical evidence has demonstrated the benefit of Xofluza in several populations (otherwise-healthy, high-risk and post-exposure prophylaxis). Xofluza is being further studied in a Phase III development program, including children under the age of one (NCT03653364) as well as to assess the potential to reduce transmission of influenza from an infected person to healthy people (NCT03969212).

Xofluza was discovered by Shionogi & Co., Ltd. and is being further developed and commercialized globally in collaboration with the Roche Group (which includes Genentech in the U.S.) and Shionogi & Co., Ltd. Under the terms of this agreement, Roche holds worldwide rights to Xofluza excluding Japan and Taiwan, which will be retained exclusively by Shionogi & Co., Ltd.

Xofluza U.S. Indication

XOFLUZA is a prescription medicine used to:

  • Treat the flu (influenza) in people 12 years of age and older who have had flu symptoms for no more than 48 hours.
  • Prevent the flu in people 12 years of age and older following contact with a person who has the flu.

It is not known if XOFLUZA is safe and effective in children less than 12 years of age.

Important Safety Information

Do not take XOFLUZA if you are allergic to baloxavir marboxil or any of the ingredients in XOFLUZA.

  • Tell your healthcare provider about all of your medical conditions, including if you are:

    • Pregnant or plan to become pregnant. It is not known if XOFLUZA can harm your unborn baby.
    • Breastfeeding or plan to breastfeed. It is not known if XOFLUZA passes into your breast milk.
  • Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, antacids, laxatives, vitamins, and herbal supplements.

Serious side effects may include

  • Allergic reaction. Get emergency medical help right away if you develop any of the following signs or symptoms of an allergic reaction:

    • trouble breathing
    • skin rash, hives or blisters
    • swelling of your face, throat or mouth
    • dizziness or lightheadedness

The most common side effects of XOFLUZA in clinical studies were diarrhea, bronchitis, nausea, sinusitis, and headache. These are not all the possible side effects of XOFLUZA. Call your healthcare provider for medical advice about side effects.

XOFLUZA is not effective in treating or preventing infections other than influenza. Other kinds of infections can have symptoms like those of the flu or occur along with flu and may need different kinds of treatment. XOFLUZA does not prevent bacterial infections that may happen with the flu. Tell your healthcare provider if you feel worse or develop new symptoms during or after treatment with XOFLUZA or if your flu symptoms do not start to get better.

You are encouraged to report side effects to Genentech by calling 1-888-835-2555 or to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.

Please see full Prescribing Information, including Patient Product Information.

About Genentech in Influenza

Influenza is one of the most common, yet serious, infectious diseases, representing a significant threat to public health. Since 2010, the Centers for Disease Control and Prevention (CDC) estimates that influenza has resulted annually in 9 to 45 million illnesses, 140,000 to 810,000 hospitalizations and 12,000 to 61,000 deaths annually. Although vaccines are an important first line of defense in preventing influenza, there is a need for new medical options for prophylaxis and treatment. Genentech is committed to addressing the unmet need in this area through its agreement with Shionogi & Co., Ltd. to develop and commercialize Xofluza.

About Genentech

Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.

Media Contact: Lindsey Mathias (650) 467-6800

Advocacy Contact: Thea Sutton (650) 491-4964

Investor Contact: Lisa Tuomi (650) 467-8737

Karl Mahler 011 41 61 687 8503

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Infectious Diseases Biotechnology Pharmaceutical Health

MEDIA:

Logo
Logo

Heartland Express, Inc. Declares Regular Quarterly Dividend

NORTH LIBERTY, Iowa, Nov. 23, 2020 (GLOBE NEWSWIRE) — The Board of Directors of Heartland Express, Inc. (Nasdaq: HTLD) announced today the declaration of a regular quarterly cash dividend. The $0.02 per share dividend will be paid on December 18, 2020 to shareholders of record at the close of business on December 8, 2020. We currently estimate that a total of approximately $1.6 million will be paid on the Company’s 80.8 million shares of common stock. This is the Company’s seventieth consecutive quarterly cash dividend. With the payment of this dividend, the Company will have paid a total of $490.4 million in cash dividends, including three special dividends since the dividend program was implemented in the third quarter of 2003.

The press release may contain forward-looking statements, which are based on information currently available. These statements and assumptions involve certain risks and uncertainties. Actual events may differ from these expectations as specified from time to time in filings with the Securities and Exchange Commission. The Company assumes no obligation to update any forward-looking statement to the extent it becomes aware that it will not be achieved for any reason.

For further information contact
Michael J. Gerdin, CEO
Christopher A. Strain, CFO
Heartland Express, Inc.
319-626-3600



Zions Bancorporation to Present at the Goldman Sachs 2020 US Financial Services Conference

Zions Bancorporation to Present at the Goldman Sachs 2020 US Financial Services Conference

SALT LAKE CITY–(BUSINESS WIRE)–
Harris Simmons, Chairman and CEO of Zions Bancorporation (NASDAQ: ZION), will make a presentation at Goldman Sachs 2020 US Financial Services Conference on Tuesday, December 8 at 3:00 p.m. EST. A live webcast of the presentation may be accessed on the Zions Bancorporation website, zionsbancorporation.com. The webcast will also be archived and available on the website for 30 days.

Zions Bancorporation, N.A. is one of the nation’s premier financial services companies with annual net revenue of $2.8 billion in 2019 and more than $7 billion of total assets. Zions operates under local management teams and distinct brands in 11 western states: Arizona, California, Colorado, Idaho, Nevada, New Mexico, Oregon, Texas, Utah, Washington and Wyoming. The Bank is a consistent recipient of national and state-wide customer survey awards in small and middle-market banking, as well as a leader in public finance advisory services and Small Business Administration lending, recently ranking as the 9th largest provider in the U.S. of the SBA’s Paycheck Protection Program loans. In addition, Zions is included in the S&P 500 and NASDAQ Financial 100 indices. Investor information and links to local banking brands can be accessed at zionsbancorporation.com.

James Abbott

Tel: (801) 844-7637

KEYWORDS: Utah United States North America

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

C.K. McWhorter, Chairman and CEO of CTRL USA, set to invest $400 million + in the acquisition & development of mixed use properties within Wellington, Florida.

PALM BEACH, Fla., Nov. 23, 2020 (GLOBE NEWSWIRE) — A new mixed-use development; retail, fine dining and luxury condominium location is coming to the Wellington/Palm Beach area.

Phase I of the project, which will include a $250 million allocation of capital dedicated to new acquisition/construction, will include much of the luxury retail/condominium development and a variety of fine dining.

“We are delighted to announce our commitment of capital to such a beautiful area. With equestrian sporting events in the U.S. destined for growth within the heart of the world’s current and coming generations, Wellington is adept to continue meeting the beauty and luxury demand of the equestrian sporting arena. CTRL USA has a long and successful presence within extraordinary investment opportunities. I look forward to expanding our role in the City of Wellington with these exceptional new destinations,” said McWhorter, chairman and chief executive officer of CTRL USA. “CTRL USA pledges to design a magnificent location that will offer unrivaled hospitality, as well as fine dining and luxury retail locations, and enhance Wellington’s reputation as an unparalleled luxury destination.”

It will be looking to contest with other high-end locations within the Palm Beach area by providing more convenience to the Wellington, Florida community. Luxury retail location possibilities include; Hermes, Louis Vuitton, Gucci, Christian Louboutin, Tiffany & Co., Alexander McQueen & More.

The condominium is set to have oversized suites, a private club, as well as two swimming pools — one of which will be for the penthouse. Price Range 2M-10M.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/40c0b2aa-321a-4fd1-9266-d498ca6e1f38

 



Contact:

Mackenzie Bledsole
Relations@ctrlusa.com
Mackenzie.Bledsole@ctrlusa.com

Palayan Engages New PCAOB Registered Auditor

Windermere, FL, Nov. 23, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Palayan Resources, Inc. (the “Company” or “PLYN”) (OTCMarkets: PLYN), a publicly traded, fully reporting emerging growth company, is pleased to announce that it has engaged TAAD, LLP (“TAAD”), a PCAOB registered auditing firm, as its independent public accounting firm.  As the Company continues to grow and expand, Palayan is best served by having an auditor with qualifications to address all of the areas touched by its operations and its subsidiaries.

James Jenkins, CEO, stated that “the Company looks forward to working with the team at TAAD and believes this change will help facilitate and streamline the timing of our filings moving forward.”

Jenkins also added, “Palayan is evaluating new investment opportunities in the United States that should allow our company to diversify and expand into other areas.  We are focused on projects that generate revenue and profitability and will explore all opportunities towards that goal. To this end, our intention is to diversify our acquisitions and become more of a holding company with interests in different sectors.”

“I believe that, in this way, we can more efficiently streamline operations as we strive towards profitability,” concluded Jenkins.

Any potential acquisition will be subject to standard and customary due diligence and will focus on maximizing shareholder value. Further updates will be provided as they become available.

ABOUT PALAYAN RESOURCES, INC.

Palayan Resources, Inc. is an emerging growth company. The Company is focused on operating, developing, exploring and acquiring high-quality projects worldwide. Headquartered in Windermere, FL, Palayan Resources is aiming to build a portfolio of companies that generate revenue and profitability.

For more information:

Contact us via:

info@palayanresourcesinc.com

Phone: (407) 536-9422

Forward-Looking Statements

This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, securing necessary financing, the future of the U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations pertaining to the mining and exploration of mineral properties. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. The Company has no mineral resource or reserve estimate in any project at this time and may not have sufficient funding to thoroughly explore, drill or develop any mineral rights. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

Source: Palayan Resources, Inc.



ROSEN, A TOP RANKED LAW FIRM, Reminds Reata Pharmaceuticals, Inc. Investors of Important December 14 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – RETA

NEW YORK, Nov. 23, 2020 (GLOBE NEWSWIRE) — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between October 15, 2019 and August 7, 2020, inclusive (the “Class Period”), of the important December 14, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Reata investors under the federal securities laws.

To join the Reata class action, go to http://www.rosenlegal.com/cases-register-1970.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the MOXIe Part 2 study results were insufficient to support a single study marketing approval of omaveloxolone for the treatment of Friedreich’s ataxia (“FA”) in the U.S. without additional evidence; (2) as a result, it was foreseeably likely that the FDA would not accept marketing approval of omaveloxolone for the treatment of FA in the U.S. based on the MOXIe Part 2 study results; and (3) as a result, Reata’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 14, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1970.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or cases@rosenlegal.com.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

        Laurence Rosen, Esq.
        Phillip Kim, Esq.
        The Rosen Law Firm, P.A.
        275 Madison Avenue, 40th Floor
        New York, NY 10016
        Tel: (212) 686-1060
        Toll Free: (866) 767-3653
        Fax: (212) 202-3827
        lrosen@rosenlegal.com
        pkim@rosenlegal.com
        cases@rosenlegal.com
        www.rosenlegal.com



ROSEN, A TOP RANKED LAW FIRM, Reminds Turquoise Hill Resources Ltd. Investors of Important December 14 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm – TRQ

NEW YORK, Nov. 23, 2020 (GLOBE NEWSWIRE) — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Turquoise Hill Resources Ltd. (NYSE: TRQ) between July 17, 2018 and July 31, 2019, inclusive (the “Class Period”), of the important December 14, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Turquoise Hill investors under the federal securities laws.

To join the Turquoise Hill class action, go to http://www.rosenlegal.com/cases-register-1971.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

According to the lawsuit, throughout the Class Period and regarding the development of the Oyu Tolgoi copper-gold mine in Mongolia, defendants made false and/or misleading statements and/or failed to disclose that: (1) the stability issues were much more severe than represented and called into question the design of the mine, the projected cost and timing of production; (2) the publicly disclosed estimates of the cost, date of completion and dates for production from the underground mine were not achievable; (3) the “challenging ground conditions” were much more severe than defendants represented, and in fact made it impossible for Turquoise Hill and Rio Tinto to achieve those estimates; (4) the development capital required for the underground development of Oyu Tolgoi would cost substantially more than a billion dollars over what Turquoise Hill and Rio Tinto had represented; (5) Turquoise Hill would require additional financing and/or equity to complete the project; (6) the progress of underground development and of Oyu Tolgoi was not proceeding as planned; and (7) the “key risks” had not been “well understood and managed” but had placed the project schedule and cost into severe jeopardy. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 14, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1971.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or cases@rosenlegal.com.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com